Literature DB >> 1079792

Cellular basis for the immune response to methylcholanthrene-induced tumors in mice. Heterogeneity of effector cells.

R Kearney, A Basten, D S Nelson.   

Abstract

Immune resistance to methylcholanthrene-induced tumors has two phases, an early specific and a late non-specific phase. Both phases were found to be T-cell-dependent in vivo. Thus, adult thymectomized, irradiated, bone-marrow-protected mice bearing H-1 tumor isografts showed impaired resistance to challenge with homologous (H-1) and heterologous (H-3) tumor cells. In each case resistance was restored by injection of thymus cells. In vitro analysis of the cellular basis of resistance revealed that different mechanisms were involved in the two phases. The cytotoxic effect of immune spleen cells taken during the early specific phase was inhibited by pretreatment with anti-O serum and complement and by removal of macrophages. Neither procedure, however, interfered with the cytotoxic potential of immune spleen cells taken during the late non-specific phage of immunity. Passage of immune spleen cells through rabbit-IgG anti-mouse immunoglobulin-coated columns (which yielded a T-cell-enriched, B-cell-depleted population) resulted in abrogration of cytotoxicity whether the cells were obtained during the early or the late phase of resistance. The inability of late-phase spleen cells to kill was explicable in terms of B-cell removal since T-cells and macrophages had been shown to be ineffective at that time. In contrast, the failure of column-treated cells from the early phase to kill was found to be due to removal of adherent cells rather than B-cells since cytotoxicity (1) was abrogated by passage through control columns coated with rabbit-IgG anti-sheep red blood cell antibody which did not retain B-cells and (2) could be restored by addition of immune macrophages (from anti-O serum-treated spleens). Taken together, these results indicate that the cellular basis of immune resistance to methylcholanthrene-induced tumors is heterogeneous. The early specific phase seems to be mediated by an interaction between T-cells and macrophages; the late none-specific phase, although T-cell dependent in its induction, depends on a different effector mechanism, possibly involving a cell or its products of the B lineage.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1079792     DOI: 10.1002/ijc.2910150310

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

Review 1.  Macrophages: progress and problems.

Authors:  D S Nelson
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

2.  Role of a non-committed accessory cell in the in vivo suppression of a syngeneic tumour by immune lymphocytes.

Authors:  R J Simes; R Kearney; D S Nelson
Journal:  Immunology       Date:  1975-08       Impact factor: 7.397

3.  The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice.

Authors:  A Vyakarnam; P J Lachmann; K Sikora
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

4.  Establishment and control of the L5178Y-cell tumor dormant state in DBA/2 mice.

Authors:  E F Wheelock; M K Robinson; G A Truitt
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

5.  Effect of immunosuppression on the growth of six murine tumors.

Authors:  K Pavelic; I Hrsak
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-09-28

6.  T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites.

Authors:  R J North; D P Kirstein
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

7.  Subversion of host defense mechanisms by malignant tumors: an established tumor as a privileged site for bacterial growth.

Authors:  G L Spitalny; R J North
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

8.  Macrophages and lymphoid tissues in mice with concomitant tumour immunity.

Authors:  D S Nelson; R Kearney
Journal:  Br J Cancer       Date:  1976-09       Impact factor: 7.640

9.  In vitro induction of tumour-specific immunity V. Detection of common antigenic determinatnts of murine fibrosarcomas.

Authors:  R C Burton; N L Warner
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

10.  Potentiation of tumour growth by endotoxin in serum from syngeneic tumour-bearing mice.

Authors:  R Kearney; P Harrop
Journal:  Br J Cancer       Date:  1980-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.